Janone technologies announces registered direct offering of common stock priced at-the-market

Las vegas , march 23, 2023 /prnewswire/ -- janone (nasdaq: jan), a biopharmaceutical company specializing in developing non-addicting pain killers and treatments for underlying causes of pain, today announced that it has entered into a definitive securities purchase agreement for the purchase and sale of 361,000 shares of the company's common stock at a purchase price of $1.17 per share of common stock in a registered direct offering priced at-the-market under nasdaq rules. the closing of the offering is expected to occur on or about march 24, 2023, subject to the satisfaction of customary closing conditions.
JAN Ratings Summary
JAN Quant Ranking